Benzinga | Jun 17, 2021 08:10AM EDT

From CureVac Webcast To Discuss Phase 2b/3 Trial Of Its COVID-19 Vaccine Candidate: CEO Says Its Study Is 'Unmatched' In Its Geographic Footprint, Study Enrolled 40K Participants In 10 Countries

-Dow Jones